Opus Genetics, Inc. (IRD) insider files to sell 7,783 shares under Rule 144

Rhea-AI Filing Summary

Robert E. Gagnon filed a notice to sell common stock of Opus Genetics, Inc. under Rule 144. The planned sale covers 7,783 shares of common stock with an aggregate market value of $23,738.15, to be executed through Jefferies LLC on or after 07/23/2026 on the NASDAQ market. The filing notes that 83,000,000 shares of this class of common stock are outstanding. The shares derive from vested restricted stock units dated 01/22/2026. In the prior three months, Gagnon reported having sold 7,842 shares of Opus Genetics common stock for an aggregate value of $40,657.63 on 04/23/2026.

Key Figures

Shares to be sold: 7,783 shares Aggregate market value of planned sale: $23,738.15 Shares outstanding: 83,000,000 shares +4 more

7 metrics

Shares to be sold 7,783 shares Common stock of Opus Genetics to be sold under Rule 144

Aggregate market value of planned sale $23,738.15 Value of 7,783 Opus Genetics common shares to be sold

Shares outstanding 83,000,000 shares Outstanding Opus Genetics common stock of the class to be sold

Prior 3-month shares sold 7,842 shares Opus Genetics common shares sold on 04/23/2026

Aggregate value of prior sale $40,657.63 Value of 7,842 Opus Genetics shares sold on 04/23/2026

RSU vesting date 01/22/2026 Date vested restricted stock units in Opus Genetics became common stock

Planned sale date 07/23/2026 Date from which the Rule 144 sale may occur

Key Terms

Form 144, Rule 144, Vested Restricted Stock Units, aggregate market value

4 terms

Form 144 regulatory

"144: Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"144: Securities To Be Sold"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Vested Restricted Stock Units financial

"Common | 01/22/2026 | Vested Restricted Stock Units | Opus Genetics, Inc."

aggregate market value financial

"7783 | 23738.15 | 83000000 | 07/23/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 05:22 PM Accepted by SEC EDGAR 07/23/2026 - 05:21 PM Learn about SEC filing dates

FAQ

What does the Form 144 filing related to IRD disclose about Opus Genetics stock?

It discloses that Robert E. Gagnon intends to sell 7,783 shares of Opus Genetics, Inc. common stock under Rule 144, with an aggregate market value of $23,738.15, through Jefferies LLC on or after 07/23/2026.

How many Opus Genetics shares is Robert E. Gagnon planning to sell?

Robert E. Gagnon plans to sell 7,783 shares of Opus Genetics common stock. The filing shows an aggregate market value of $23,738.15 for these shares, with sales expected to occur on or after 07/23/2026 via Jefferies LLC on NASDAQ.

What prior Opus Genetics stock sales are reported in the Form 144 linked to IRD?

The filing reports that on 04/23/2026, 7,842 shares of Opus Genetics common stock were sold for an aggregate value of $40,657.63. This reflects securities sold during the three months preceding the planned new Rule 144 sale.

What is the source of the Opus Genetics shares covered by this Form 144?

The common shares to be sold come from vested restricted stock units in Opus Genetics, Inc. These restricted stock units vested on 01/22/2026, and the resulting common stock is now being noticed for potential sale under Rule 144.

How many Opus Genetics shares are outstanding according to this Form 144?

The Form 144 states that there are 83,000,000 shares of Opus Genetics common stock outstanding. This figure provides context for the 7,783 shares that Robert E. Gagnon plans to sell under Rule 144 through Jefferies LLC.

Which broker and market are involved in the planned Opus Genetics share sale?

The planned sale of 7,783 shares of Opus Genetics common stock will be handled by Jefferies LLC and is expected to take place on the NASDAQ market. The aggregate market value indicated for this transaction is $23,738.15.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave New York NY 10022	7783	23738.15	83000000	07/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/22/2026	Vested Restricted Stock Units	Opus Genetics, Inc.			7783	01/22/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Robert E Gagnon 8 Davis Drive, Ste. 220 Durham NC 27709	Opus Genetics, Inc.	04/23/2026	7842	40657.63

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)